ArticleSmall (Weinheim an der Bergstrasse, Germany)2011
Multifunctional mesoporous silica nanospheres with cleavable Gd(III) chelates as MRI contrast agents: synthesis, characterization, target-specificity, and renal clearance.
Article in Small (Weinheim an der Bergstrasse, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 109 citations in OpenAlex.
- Bibliometric analysis of current trends and emerging patterns in the application of nanomaterials for non-small cell lung cancer.Discover oncology · 2025Article
- Functionalized Nanomaterials In Pancreatic Cancer Theranostics And Molecular Imaging.ChemistryOpen · 2025Review
- New insights into nanosystems for non-small-cell lung cancer: diagnosis and treatment.RSC advances · 2023Review
- A toxicological profile of silica nanoparticles.Toxicology research · 2022Review
- Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?Chemical Society reviews · 2022Review
- Mesoporous Silica Nanoparticle-Based Imaging Agents for Hepatocellular Carcinoma Detection.Frontiers in bioengineering and biotechnology · 2021Article
- The Renal Clearable Magnetic Resonance Imaging Contrast Agents: State of the Art and Recent Advances.Molecules (Basel, Switzerland) · 2020Review
- Photo-responsive degradable hollow mesoporous organosilica nanoplatforms for drug delivery.Journal of nanobiotechnology · 2020Article
- Nanomaterials: Applications in the diagnosis and treatment of pancreatic cancer.World journal of gastrointestinal pharmacology and therapeutics · 2020Review
- Bioceramics: from bone substitutes to nanoparticles for drug delivery.Pure and applied chemistry. Chimie pure et appliquee · 2019Article
- Theragnostic potentials of core/shell mesoporous silica nanostructures.Nanotheranostics · 2019Review
- A Toolbox for the Synthesis of Multifunctionalized Mesoporous Silica Nanoparticles for Biomedical Applications.ACS omega · 2018Article
- Stearic Acid-Grafted Chitooligosaccharide Nanomicelle System with Biocleavable Gadolinium Chelates as a Multifunctional Agent for Tumor Imaging and Drug Delivery.Pharmaceutical research · 2018Article
- Mesoporous silica nanoparticles in nanomedicine applications.Journal of materials science. Materials in medicine · 2018Review
- Review
- Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights.Molecules (Basel, Switzerland) · 2017Review
- Biocompatibility of Multi-Imaging Engineered Mesoporous Silica Nanoparticles:Journal of biomedical nanotechnology · 2017Article
- Advanced Functional Nanomaterials for Theranostics.Advanced functional materials · 2017Article
- Gd-Si Oxide Nanoparticles as Contrast Agents in Magnetic Resonance Imaging.Nanomaterials (Basel, Switzerland) · 2016Article
- Mesoporous Silica Nanoparticles Loaded with Cisplatin and Phthalocyanine for Combination Chemotherapy and Photodynamic TherapyNanomaterials (Basel, Switzerland) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Mesoporous silica nanospheres (MSNs) are a promising material for magnetic resonance imaging (MRI) contrast agents. In this paper multifunctional MSNs with cleavable Gd(III) chelates are synthesized and characterized, and their applicability as MRI contrast agents is demonstrated both in vitro and in vivo. The MSNs contain Gd(III) chelates that are covalently linked via a redox-responsive disulfide moiety. The MSNs are further functionalized with polyethylene glycol (PEG) and an anisamide ligand to improve their biocompatibility and target specificity. The effectiveness of MSNs as an MRI imaging contrast agent and their targeting ability are successfully demonstrated in vitro using human colon adenocarcinoma and pancreatic cancer cells. Finally, the capability of this platform as an in vivo MRI contrast agent is tested using a 3T scanner. The Gd(III) chelate was quickly cleaved by the blood pool thiols and eliminated through the renal excretion pathway. Further tuning of the Gd(III) chelate release kinetics is needed before the MSN system can be used as target-specific MRI contrast agents in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.